Beijing Tiantan Biological Products 将来の成長

Future 基準チェック /26

Beijing Tiantan Biological Products利益と収益がそれぞれ年間19.7%と19.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に14% 20.6%なると予測されています。

主要情報

19.7%

収益成長率

20.6%

EPS成長率

Biotechs 収益成長	43.4%
収益成長率	19.6%
将来の株主資本利益率	14.0%
アナリストカバレッジ	Good
最終更新日	06 Nov 2024

今後の成長に関する最新情報

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29

Recent updates

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Oct 27

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Oct 08

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Sep 19

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Jul 23

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 09

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

May 22

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Mar 01

業績と収益の成長予測

SHSE:600161 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8,211	1,975	1,820	2,459	8
12/31/2025	7,131	1,648	1,589	2,510	7
12/31/2024	5,928	1,361	1,082	1,160	3
9/30/2024	5,232	1,274	270	1,351	N/A
6/30/2024	5,331	1,269	1,183	2,328	N/A
3/31/2024	5,110	1,165	1,087	2,242	N/A
12/31/2023	5,180	1,110	1,316	2,394	N/A
9/30/2023	5,371	1,167	1,254	2,515	N/A
6/30/2023	5,062	1,063	341	1,633	N/A
3/31/2023	4,848	1,018	250	1,539	N/A
12/31/2022	4,261	881	-228	1,126	N/A
9/30/2022	4,207	803	-195	1,097	N/A
6/30/2022	4,191	808	-187	1,117	N/A
3/31/2022	3,970	733	-351	918	N/A
12/31/2021	4,112	760	-151	980	N/A
9/30/2021	3,628	700	-241	728	N/A
6/30/2021	3,702	692	-120	640	N/A
3/31/2021	3,535	659	-71	571	N/A
12/31/2020	3,446	639	93	702	N/A
9/30/2020	3,398	641	306	755	N/A
6/30/2020	3,276	601	362	877	N/A
3/31/2020	3,334	611	184	741	N/A
12/31/2019	3,282	611	116	642	N/A
9/30/2019	3,394	580	282	788	N/A
6/30/2019	3,271	563	376	801	N/A
3/31/2019	3,083	531	729	1,028	N/A
12/31/2018	2,931	509	384	678	N/A
9/30/2018	2,929	568	538	767	N/A
6/30/2018	2,671	532	N/A	590	N/A
3/31/2018	2,485	1,228	N/A	186	N/A
12/31/2017	2,483	1,173	N/A	138	N/A
9/30/2017	2,362	1,077	N/A	301	N/A
6/30/2017	2,256	1,038	N/A	280	N/A
3/31/2017	2,330	313	N/A	344	N/A
12/31/2016	2,138	257	N/A	433	N/A
9/30/2016	1,756	151	N/A	251	N/A
6/30/2016	1,709	55	N/A	403	N/A
3/31/2016	1,624	-3	N/A	471	N/A
12/31/2015	1,618	10	N/A	473	N/A
9/30/2015	1,545	-88	N/A	384	N/A
6/30/2015	1,567	-46	N/A	382	N/A
3/31/2015	1,723	46	N/A	560	N/A
12/31/2014	1,827	128	N/A	478	N/A
9/30/2014	2,026	291	N/A	748	N/A
6/30/2014	2,018	377	N/A	705	N/A
3/31/2014	1,905	371	N/A	490	N/A
12/31/2013	1,837	372	N/A	566	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600161の予測収益成長率 (年間19.7% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 600161の収益 ( 19.7% ) CN市場 ( 26.2% ) よりも低い成長が予測されています。

高成長収益: 600161の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 600161の収益 ( 19.6% ) CN市場 ( 13.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: 600161の収益 ( 19.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600161の自己資本利益率は、3年後には低くなると予測されています ( 14 %)。

Beijing Tiantan Biological Products 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Price target increased by 11% to CN¥33.90

Recent updates

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Dividend sustainability

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 23%

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Second quarter 2024 earnings: EPS misses analyst expectations

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 20%

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Price target increased by 11% to CN¥33.90

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Now 27% overvalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd., Annual General Meeting, May 29, 2024

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.53 in FY 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 3Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.075 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from S&P Global BMI Index

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from FTSE All-World Index (USD)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 3Q 2021)

Now 20% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2021)

Now 20% undervalued

Now 21% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

Now 24% undervalued after recent price drop

Less than half of directors are independent

Now 20% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 1Q 2020)

New 90-day low: CN¥36.46

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.50

New 90-day high: CN¥41.95

Beijing Tiantan Biological Products Co., Ltd. announced that it expects to receive CNY 3.34 billion in funding

Third quarter earnings released

New 90-day low: CN¥37.99

First half earnings released

First half earnings released

New 90-day high - CN¥42.80

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘